Endotronix, a digital health startup developing a implantable, wireless pulmonary artery sensor for patients suffering from advanced heart failure has raised $32 million in Series C funding. Participating investors in the round include BioVentures Investors, SV Life Sciences (SVLS), Lumira Capital, Aperture Venture Partners, and OSF Ventures along with existing investors and a corporate strategic investor.
The company plans to use the funding from the round to support the safety and feasibility study for their implantable wireless pulmonary artery sensor and commercialization of their outpatient management system.
Founded in 2007 by a mechanical engineer and a cardiothoracic surgeon, Endotronix‘s solution combines a cloud-based patient management system and an implantable pulmonary artery sensor for improved outpatient hemodynamic management.
Real-time monitoring of pulmonary artery pressures has been shown to reduce heart failure hospitalizations by as much as 37%. The Endotronix wireless solution seamlessly integrates daily clinical monitoring of key physiological data with improved communication between patients, caregivers and clinicians for earlier detection of worsening heart failure.
Nearly 6 million Americans live with heart failure. It is the leading cause of hospitalization for people over 65 with annual treatment costs exceeding $31 billion. The technology under development at Endotronix will result in early patient intervention and offers the promise to significantly reduce costs to the healthcare system while dramatically improving patient care.
